Drug intelligence / Profile preview

mi-463

Development stage: Preclinical
Lead developer: Kura Oncology
Modality: Small Molecules
Administration: Oral

Overview

MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-MLL interaction. It demonstrates profound on-target activity in MLL leukemia cells, with an IC50 value of 15.3 nM for inhibiting the menin-MLL interaction. MI-463 has shown efficacy in blocking the progression of mixed lineage leukemia (MLL) both in vitro and in vivo, including reducing tumor growth in mouse xenograft models at 35 mg/kg[2][5][6]. The drug is currently for research use only and not approved for clinical use.

Targets

MEN1 (Menin)

Beyond the preview

Go deeper on mi-463.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mi-463.

Explore the full profile